Details About Generic Salt ::  Zaleplon

Main Medicine Class:: Sedative and hypnotic   

(ZAL-eh-plahn)

Sonata

Class: Sedative and hypnotic

Drugs Class ::

 Action Interacts with the gamma-aminobutyric acid receptor complex.

Indications for Drugs ::

 Indications Short-term treatment of insomnia.

Drug Dose ::

 Route/Dosage

ADULTS: PO 5 to 20 mg at bedtime. ELDERLY/DEBILITATED PATIENTS: PO 5 to 10 mg at bedtime. HEPATIC IMPAIRMENT (MILD TO MODERATE): PO 5 mg at bedtime.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Elderly: Impaired motor or cognitive function with repeated exposure or unusual sensitivity is a concern. Amnesia: May occur. Depression: Administer with caution to depressed patients or those with suicidal tendencies. Signs and symptoms of depression may be intensified. Hepatic impairment: Use with caution and in reduced dosage. Withdrawal: Rebound insomnia on the first night following withdrawal occurs in some patients.

Drug Side Effects ::

 Adverse Reactions

CV: Migraine. RESP: Bronchitis; epistaxis. CNS: Depression; hypertonia; nervousness; abnormal thinking; headache; anxiety; amnesia; dizziness; depersonalization; hallucinations; hypesthesia; paresthesia; somnolence; tremor; vertigo. EENT: Conjunctivitis; abnormal vision; ear pain; eye pain; hyperacusis; parosmia. GI: Constipation; dry mouth; anorexia; colitis; dyspepsia; nausea. GU: Dysmenorrhea. DERM: Pruritus; rash; photosensitivity. OTHER: Back pain; chest pain; arthritis; abdominal pain; asthenia; fever; malaise; peripheral edema.

Drug Mode of Action ::  

 Action Interacts with the gamma-aminobutyric acid receptor complex.

Drug Interactions ::

 Interactions

Alcohol, other CNS depressants: Additive or potentiation of CNS depressant effects. Cimetidine: May elevate zaleplon plasma levels, increasing the therapeutic and adverse effects. Rifampin: May reduce zaleplon plasma levels, reducing the effectiveness.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Ensure that side rails are raised after administration.
• Assist patient with ambulation after administration.
• Assess depressed patient for suicidal thoughts and if present, institute protective measures.
• Monitor for problems of tolerance, dependence, changes in behavior and thinking, memory problems, and withdrawal symptoms if medication is abruptly stopped.

Drug Storage/Management ::

 Administration/Storage

• Store at room temperature in tightly closed, light-resistant container out of the reach of children.
• Do not administer with or immediately after a high fat or heavy meal.
• Anticipate administering the lowest dose possible, especially to patients at risk (ie, elderly and patients with decreased hepatic function).

Drug Notes ::

 Patient/Family Education

• Instruct patient to take the medication exactly as directed and not to increase or decrease the dose or use longer than as directed by primary caregiver.
• Instruct patient to take zaleplon immediately before going to bed or after going to bed if patient has difficulty falling asleep. Avoid taking medication after a high-fat or heavy meal.
• Instruct patient not to take zaleplon if able to get ³ 4 hours of sleep before active again and only for a short period of time (1 or 2 days and generally < 1 or 2 weeks) to avoid the problems of prolonged use.
• Discuss with primary caregiver the benefits and risks of prolonged use including memory problems, tolerance, dependence, changes in behavior and thinking, and withdrawal symptoms.
• Instruct patient to inform primary caregiver if taking or planning to take any otc or prescription medications.
• Warn patient of the dangers of drinking alcohol and taking zaleplon or any other sleeping pill or CNS depressant.
• Caution patient that zaleplon may have some residual sedation at first and to not drive an automobile, operate dangerous machinery, or engage in activities that require mental alertness and coordination until knowing how he/she will react to this drug.
• Instruct patient to inform primary caregiver if having any unusual or disturbing thoughts or suffering from depression.
• Inform patient of potential sleeping problems the first night or 2 after stopping the medication.
• Caution patient to inform the primary caregiver if pregnant, planning to become pregnant, or breastfeeding.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.